![]() ![]() I also serve on the board of the National Venture Capital Association and the Penn State Research Foundation.Īs a British Marshall Scholar, I received a D.Phil. I serve as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. ![]() While at McKinsey, I worked a lot with pharmaceutical and biotechnology firms to address R&D productivity issues, as well as portfolio management, new product commercialization, and business development. Prior to Atlas, I was an investor with Caxton Health Holdings and before that, a consultant at McKinsey & Company, a global strategic management consulting firm. Previously, I enjoyed serving on the boards of past Atlas companies Avila Therapeutics (acquired by Celgene), miRagen Therapeutics (NASDAQ:MGEN), Padlock Therapeutics (acquired by BMS), Stromedix (acquired by Biogen), Prestwick (acquired by Biovail), and Proprius (acquired by Cypress Biosciences), among others. ![]() I also serve on the boards of Lysosomal Therapeutics, and Magenta Therapeutics (NASDAQ:MGTA). I’m co-founder/founding investor and currently board chair of AvroBio (NASDAQ:AVRO), Arkuda Therapeutics, Kymera Therapeutics, Hotspot Therapeutics, Nimbus Therapeutics, Quench Bio, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX). Since joining Atlas in 2005, I’ve been involved in the founding and funding a number of innovative companies, with a particular focus on capital efficient models for drug R&D. In short, we focus on seed-led venture creation around the discovery and development of novel therapeutics. Like my partners at Atlas Venture, I enjoy working with great scientists and entrepreneurs to start new biotech companies. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |